Cannabidiol (CBD) and cannabigerol (CBG) are Cannabis sativa terpenophenols. Although CBD’s effectiveness against neurological diseases has already been demonstrated, nothing is known about CBG. Therefore, a comparison of the effects of these compounds was performed in two experimental models mimicking the oxidative stress and neurotoxicity occurring in neurological diseases. Rat astrocytes were exposed to hydrogen peroxide and cell viability, reactive oxygen species production and apoptosis occurrence were investigated. Cortexes were exposed to K+ 60 mM depolarizing stimulus and serotonin (5-HT) turnover, 3-hydroxykinurenine and kynurenic acid levels were measured. A proteomic analysis and bioinformatics and docking studies were performed. Both compounds exerted antioxidant effects in astrocytes and restored the cortex level of 5-HT depleted by neurotoxic stimuli, whereas sole CBD restored the basal levels of 3-hydroxykinurenine and kynurenic acid. CBG was less effective than CBD in restoring the levels of proteins involved in neurotransmitter exocytosis. Docking analyses predicted the inhibitory effects of these compounds towards the neurokinin B receptor. Conclusion: The results in the in vitro system suggest brain non-neuronal cells as a target in the treatment of oxidative conditions, whereas findings in the ex vivo system and docking analyses imply the potential roles of CBD and CBG as neuroprotective agents.
Keywords: apoptosis; cannabidiol; cannabigerol; docking; exocytosis; neuroprotection; oxidative stress; proteomic analysis; serotonin.
Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus.
Antioxidants (Basel). 2020 Jan 13;9(1):71. doi: 10.3390/antiox9010071. Antioxidants (Basel). 2020. PMID: 31941059 Free PMC article.
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
Psychopharmacology (Berl). 2011 Jun;215(3):505-12. doi: 10.1007/s00213-010-2157-4. Epub 2011 Jan 18. Psychopharmacology (Berl). 2011. PMID: 21243485
In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid.
Int J Mol Sci. 2018 Jul 8;19(7):1992. doi: 10.3390/ijms19071992. Int J Mol Sci. 2018. PMID: 29986533 Free PMC article.
Molecular Targets of Cannabidiol in Neurological Disorders.
Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3. Neurotherapeutics. 2015. PMID: 26264914 Free PMC article. Review.
Cannabidiol Adverse Effects and Toxicity.
Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.